Current Report Filing (8-k)
11 March 2023 - 08:06AM
Edgar (US Regulatory)
0001501697FALSE00015016972023-03-102023-03-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 10, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
X4 PHARMACEUTICALS, INC. |
|
(Exact name of registrant as specified in its charter) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware |
|
001-38295 |
|
27-3181608 |
|
(State or other
jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
|
|
|
|
|
|
61 North Beacon Street, |
4th Floor |
|
|
|
Boston, |
Massachusetts |
|
02134 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(857) 529-8300
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last
report)
_______________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐ Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, par value $0.001 per share |
|
XFOR |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2
of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On March 10, 2023, the Federal Deposit Insurance Corporation
(“FDIC”) issued a press release stating that Silicon Valley Bank,
Santa Clara, California, (“SVB”) was closed by the California
Department of Financial Protection and Innovation, which appointed
the FDIC as receiver. To protect insured depositors, the FDIC
created the Deposit Insurance National Bank of Santa Clara
(“DINB”). At the time of closing, the FDIC as receiver immediately
transferred all insured deposits of SVB.
As of December 31, 2022, X4 Pharmaceuticals Inc. (the “Company”)
had approximately 2.5% of its cash deposits with SVB. According to
the FDIC, all insured depositors will have full access to their
insured deposits no later than Monday, March 13, 2023. The FDIC
will pay uninsured depositors an advance dividend within the next
week. Uninsured depositors will receive a receivership certificate
for the remaining amount of their uninsured funds. As the FDIC
sells the assets of Silicon Valley Bank, future dividend payments
may be made to uninsured depositors.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934
the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
X4 PHARMACEUTICALS, INC. |
|
|
|
|
|
Date: March 10, 2023 |
|
By: |
/s/ Adam Mostafa |
|
|
|
Adam Mostafa |
|
|
|
Chief Financial Officer |
X4 Pharmaceuticals (NASDAQ:XFOR)
Historical Stock Chart
From May 2023 to Jun 2023
X4 Pharmaceuticals (NASDAQ:XFOR)
Historical Stock Chart
From Jun 2022 to Jun 2023
